News

Article

Alnylam Moves Forward on Multi-Product RNAi Facility

Jacobs Engineering Group was awarded a contract to provide engineering services and procurement for Alnylam Pharmaceuticals’ new manufacturing facility in Norton, Massachusetts.

Alnylam Pharmaceuticals, an RNAi therapeutics company, broke ground on a biopharmaceutical manufacturing facility in Norton, Massachusetts to supply RNA interference-based therapeutics for its clinical and commercial needs, the company announced on April 28, 2016. In an Aug. 4, 2016 press release, Jacobs Engineering Group announced that it was awarded a contract to provide engineering services and procurement for the facility. Construction on the 200,000-ft2 facility is expected to be completed in 2018, and it will initially employ approximately 150 new full-time employees.

“This flagship multi-product facility represents a key next step in Alnylam’s transition toward a commercial stage company. Increased manufacturing capability is vital to support our rapidly growing pipeline of 10 clinical stage programs, two of which are in Phase 3 trials,” said John Maraganore, CEO of Alnylam, in the release.

Sources: Jacobs, Alnylam

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content